Bluejay Diagnostics, Inc. (BJDX) Stock Competitors & Peer Comparison
See (BJDX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BJDX | $4.65 | +2.42% | 2.1M | -1.21 | -$3.74 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $88.38 | -2.47% | 154.1B | 24.78 | $3.57 | +2.70% |
| ISRG | $402.03 | -3.61% | 142.4B | 48.75 | $8.25 | N/A |
| SYK | $301.28 | -2.99% | 115.4B | 34.81 | $8.65 | +1.11% |
| MDT | $78.17 | -3.87% | 100.3B | 20.73 | $3.77 | +3.50% |
| BSX | $45.02 | -4.05% | 66.8B | 18.81 | $2.39 | N/A |
| EW | $86.45 | -2.40% | 49.9B | 46.86 | $1.85 | N/A |
| DXCM | $71.21 | -2.67% | 27.5B | 30.57 | $2.33 | N/A |
| RMD | $186.00 | -4.09% | 27B | 17.97 | $10.37 | +1.23% |
Stock Comparison
BJDX vs BSX-PA Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BJDX is priced at $4.65, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BJDX's ROE is -1.44%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, BJDX is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check BSX-PA's competition here
BJDX vs ABT Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, ABT has a market cap of 154.1B. Regarding current trading prices, BJDX is priced at $4.65, while ABT trades at $88.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas ABT's P/E ratio is 24.78. In terms of profitability, BJDX's ROE is -1.44%, compared to ABT's ROE of +0.12%. Regarding short-term risk, BJDX is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check ABT's competition here
BJDX vs ISRG Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, ISRG has a market cap of 142.4B. Regarding current trading prices, BJDX is priced at $4.65, while ISRG trades at $402.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas ISRG's P/E ratio is 48.75. In terms of profitability, BJDX's ROE is -1.44%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, BJDX is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check ISRG's competition here
BJDX vs SYK Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, SYK has a market cap of 115.4B. Regarding current trading prices, BJDX is priced at $4.65, while SYK trades at $301.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas SYK's P/E ratio is 34.81. In terms of profitability, BJDX's ROE is -1.44%, compared to SYK's ROE of +0.15%. Regarding short-term risk, BJDX is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check SYK's competition here
BJDX vs MDT Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, MDT has a market cap of 100.3B. Regarding current trading prices, BJDX is priced at $4.65, while MDT trades at $78.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas MDT's P/E ratio is 20.73. In terms of profitability, BJDX's ROE is -1.44%, compared to MDT's ROE of +0.10%. Regarding short-term risk, BJDX is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check MDT's competition here
BJDX vs BSX Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, BSX has a market cap of 66.8B. Regarding current trading prices, BJDX is priced at $4.65, while BSX trades at $45.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas BSX's P/E ratio is 18.81. In terms of profitability, BJDX's ROE is -1.44%, compared to BSX's ROE of +0.15%. Regarding short-term risk, BJDX is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check BSX's competition here
BJDX vs EW Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, EW has a market cap of 49.9B. Regarding current trading prices, BJDX is priced at $4.65, while EW trades at $86.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas EW's P/E ratio is 46.86. In terms of profitability, BJDX's ROE is -1.44%, compared to EW's ROE of +0.11%. Regarding short-term risk, BJDX is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check EW's competition here
BJDX vs DXCM Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, DXCM has a market cap of 27.5B. Regarding current trading prices, BJDX is priced at $4.65, while DXCM trades at $71.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas DXCM's P/E ratio is 30.57. In terms of profitability, BJDX's ROE is -1.44%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, BJDX is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check DXCM's competition here
BJDX vs RMD Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, RMD has a market cap of 27B. Regarding current trading prices, BJDX is priced at $4.65, while RMD trades at $186.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas RMD's P/E ratio is 17.97. In terms of profitability, BJDX's ROE is -1.44%, compared to RMD's ROE of +0.24%. Regarding short-term risk, BJDX is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check RMD's competition here
BJDX vs PHG Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, PHG has a market cap of 25.5B. Regarding current trading prices, BJDX is priced at $4.65, while PHG trades at $26.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas PHG's P/E ratio is 22.62. In terms of profitability, BJDX's ROE is -1.44%, compared to PHG's ROE of +0.09%. Regarding short-term risk, BJDX is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check PHG's competition here
BJDX vs STE Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, STE has a market cap of 19.4B. Regarding current trading prices, BJDX is priced at $4.65, while STE trades at $198.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas STE's P/E ratio is 25.13. In terms of profitability, BJDX's ROE is -1.44%, compared to STE's ROE of +0.11%. Regarding short-term risk, BJDX is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check STE's competition here
BJDX vs ABMD Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BJDX is priced at $4.65, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BJDX's ROE is -1.44%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BJDX is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check ABMD's competition here
BJDX vs ZBH Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, ZBH has a market cap of 16.9B. Regarding current trading prices, BJDX is priced at $4.65, while ZBH trades at $87.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas ZBH's P/E ratio is 22.59. In terms of profitability, BJDX's ROE is -1.44%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BJDX is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check ZBH's competition here
BJDX vs SNN Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, BJDX is priced at $4.65, while SNN trades at $30.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas SNN's P/E ratio is 21.01. In terms of profitability, BJDX's ROE is -1.44%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BJDX is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check SNN's competition here
BJDX vs SWAV Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BJDX is priced at $4.65, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BJDX's ROE is -1.44%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BJDX is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check SWAV's competition here
BJDX vs PEN Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, PEN has a market cap of 12.4B. Regarding current trading prices, BJDX is priced at $4.65, while PEN trades at $316.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas PEN's P/E ratio is 73.02. In terms of profitability, BJDX's ROE is -1.44%, compared to PEN's ROE of +0.12%. Regarding short-term risk, BJDX is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check PEN's competition here
BJDX vs ALGN Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, BJDX is priced at $4.65, while ALGN trades at $173.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas ALGN's P/E ratio is 29.21. In terms of profitability, BJDX's ROE is -1.44%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, BJDX is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check ALGN's competition here
BJDX vs GMED Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, GMED has a market cap of 10.2B. Regarding current trading prices, BJDX is priced at $4.65, while GMED trades at $75.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas GMED's P/E ratio is 17.62. In terms of profitability, BJDX's ROE is -1.44%, compared to GMED's ROE of +0.13%. Regarding short-term risk, BJDX is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check GMED's competition here
BJDX vs PODD Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, PODD has a market cap of 9.9B. Regarding current trading prices, BJDX is priced at $4.65, while PODD trades at $143.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas PODD's P/E ratio is 33.53. In terms of profitability, BJDX's ROE is -1.44%, compared to PODD's ROE of +0.21%. Regarding short-term risk, BJDX is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check PODD's competition here
BJDX vs MASI Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BJDX is priced at $4.65, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas MASI's P/E ratio is 44.43. In terms of profitability, BJDX's ROE is -1.44%, compared to MASI's ROE of +0.09%. Regarding short-term risk, BJDX is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check MASI's competition here
BJDX vs BRKRP Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, BRKRP has a market cap of 8.3B. Regarding current trading prices, BJDX is priced at $4.65, while BRKRP trades at $410.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas BRKRP's P/E ratio is N/A. In terms of profitability, BJDX's ROE is -1.44%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, BJDX is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check BRKRP's competition here
BJDX vs BRKR Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, BRKR has a market cap of 8.3B. Regarding current trading prices, BJDX is priced at $4.65, while BRKR trades at $54.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas BRKR's P/E ratio is -228.04. In terms of profitability, BJDX's ROE is -1.44%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, BJDX is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check BRKR's competition here
BJDX vs BIO Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, BIO has a market cap of 7.7B. Regarding current trading prices, BJDX is priced at $4.65, while BIO trades at $284.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas BIO's P/E ratio is 47.30. In terms of profitability, BJDX's ROE is -1.44%, compared to BIO's ROE of +0.02%. Regarding short-term risk, BJDX is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check BIO's competition here
BJDX vs BIO-B Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, BIO-B has a market cap of 7.6B. Regarding current trading prices, BJDX is priced at $4.65, while BIO-B trades at $295.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas BIO-B's P/E ratio is 49.00. In terms of profitability, BJDX's ROE is -1.44%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, BJDX is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check BIO-B's competition here
BJDX vs GKOS Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, GKOS has a market cap of 7.5B. Regarding current trading prices, BJDX is priced at $4.65, while GKOS trades at $127.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas GKOS's P/E ratio is -38.62. In terms of profitability, BJDX's ROE is -1.44%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, BJDX is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check GKOS's competition here
BJDX vs NARI Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BJDX is priced at $4.65, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas NARI's P/E ratio is -59.24. In terms of profitability, BJDX's ROE is -1.44%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BJDX is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check NARI's competition here
BJDX vs LIVN Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, BJDX is priced at $4.65, while LIVN trades at $78.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas LIVN's P/E ratio is 40.05. In terms of profitability, BJDX's ROE is -1.44%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, BJDX is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check LIVN's competition here
BJDX vs AXNX Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BJDX is priced at $4.65, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BJDX's ROE is -1.44%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BJDX is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check AXNX's competition here
BJDX vs IRTC Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, IRTC has a market cap of 3.3B. Regarding current trading prices, BJDX is priced at $4.65, while IRTC trades at $101.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas IRTC's P/E ratio is -119.75. In terms of profitability, BJDX's ROE is -1.44%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, BJDX is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check IRTC's competition here
BJDX vs ITGR Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, BJDX is priced at $4.65, while ITGR trades at $89.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas ITGR's P/E ratio is 22.24. In terms of profitability, BJDX's ROE is -1.44%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, BJDX is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check ITGR's competition here
BJDX vs TMDX Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, BJDX is priced at $4.65, while TMDX trades at $73.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas TMDX's P/E ratio is 16.68. In terms of profitability, BJDX's ROE is -1.44%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, BJDX is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check TMDX's competition here
BJDX vs ESTA Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, ESTA has a market cap of 2.4B. Regarding current trading prices, BJDX is priced at $4.65, while ESTA trades at $82.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas ESTA's P/E ratio is -56.05. In terms of profitability, BJDX's ROE is -1.44%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, BJDX is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check ESTA's competition here
BJDX vs AXGN Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, AXGN has a market cap of 2.4B. Regarding current trading prices, BJDX is priced at $4.65, while AXGN trades at $44.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas AXGN's P/E ratio is -69.64. In terms of profitability, BJDX's ROE is -1.44%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, BJDX is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check AXGN's competition here
BJDX vs NUVA Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BJDX is priced at $4.65, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BJDX's ROE is -1.44%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BJDX is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check NUVA's competition here
BJDX vs UFPT Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, BJDX is priced at $4.65, while UFPT trades at $225.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas UFPT's P/E ratio is 25.90. In terms of profitability, BJDX's ROE is -1.44%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BJDX is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check UFPT's competition here
BJDX vs BFLY Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, BFLY has a market cap of 1.5B. Regarding current trading prices, BJDX is priced at $4.65, while BFLY trades at $5.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas BFLY's P/E ratio is -19.02. In terms of profitability, BJDX's ROE is -1.44%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, BJDX is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check BFLY's competition here
BJDX vs IART Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, BJDX is priced at $4.65, while IART trades at $17.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas IART's P/E ratio is -2.66. In terms of profitability, BJDX's ROE is -1.44%, compared to IART's ROE of -0.48%. Regarding short-term risk, BJDX is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check IART's competition here
BJDX vs HSKA Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BJDX is priced at $4.65, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BJDX's ROE is -1.44%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BJDX is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check HSKA's competition here
BJDX vs AHCO Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, BJDX is priced at $4.65, while AHCO trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas AHCO's P/E ratio is -16.15. In terms of profitability, BJDX's ROE is -1.44%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, BJDX is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check AHCO's competition here
BJDX vs ATEC Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, ATEC has a market cap of 1.3B. Regarding current trading prices, BJDX is priced at $4.65, while ATEC trades at $8.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas ATEC's P/E ratio is -9.93. In terms of profitability, BJDX's ROE is -1.44%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, BJDX is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check ATEC's competition here
BJDX vs ENOV Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, ENOV has a market cap of 1.2B. Regarding current trading prices, BJDX is priced at $4.65, while ENOV trades at $20.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas ENOV's P/E ratio is -1.05. In terms of profitability, BJDX's ROE is -1.44%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, BJDX is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check ENOV's competition here
BJDX vs PRCT Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, BJDX is priced at $4.65, while PRCT trades at $20.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas PRCT's P/E ratio is -12.67. In terms of profitability, BJDX's ROE is -1.44%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, BJDX is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check PRCT's competition here
BJDX vs INSP Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, BJDX is priced at $4.65, while INSP trades at $41.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas INSP's P/E ratio is 9.34. In terms of profitability, BJDX's ROE is -1.44%, compared to INSP's ROE of +0.18%. Regarding short-term risk, BJDX is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check INSP's competition here
BJDX vs AVNS Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BJDX is priced at $4.65, while AVNS trades at $24.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas AVNS's P/E ratio is -15.57. In terms of profitability, BJDX's ROE is -1.44%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BJDX is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check AVNS's competition here
BJDX vs IRMD Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, BJDX is priced at $4.65, while IRMD trades at $90.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas IRMD's P/E ratio is 49.78. In terms of profitability, BJDX's ROE is -1.44%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, BJDX is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check IRMD's competition here
BJDX vs SILK Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BJDX is priced at $4.65, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas SILK's P/E ratio is -18.96. In terms of profitability, BJDX's ROE is -1.44%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BJDX is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check SILK's competition here
BJDX vs FNA Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BJDX is priced at $4.65, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas FNA's P/E ratio is -19.83. In terms of profitability, BJDX's ROE is -1.44%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BJDX is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check FNA's competition here
BJDX vs TNDM Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, BJDX is priced at $4.65, while TNDM trades at $15.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas TNDM's P/E ratio is -11.24. In terms of profitability, BJDX's ROE is -1.44%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, BJDX is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check TNDM's competition here
BJDX vs AORT Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, AORT has a market cap of 1B. Regarding current trading prices, BJDX is priced at $4.65, while AORT trades at $21.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas AORT's P/E ratio is 84.80. In terms of profitability, BJDX's ROE is -1.44%, compared to AORT's ROE of +0.03%. Regarding short-term risk, BJDX is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check AORT's competition here
BJDX vs CNMD Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, CNMD has a market cap of 965.6M. Regarding current trading prices, BJDX is priced at $4.65, while CNMD trades at $31.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas CNMD's P/E ratio is 18.12. In terms of profitability, BJDX's ROE is -1.44%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, BJDX is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check CNMD's competition here
BJDX vs LMRI Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, LMRI has a market cap of 844.5M. Regarding current trading prices, BJDX is priced at $4.65, while LMRI trades at $8.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas LMRI's P/E ratio is -22.54. In terms of profitability, BJDX's ROE is -1.44%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, BJDX is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check LMRI's competition here
BJDX vs CSII Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BJDX is priced at $4.65, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas CSII's P/E ratio is -20.83. In terms of profitability, BJDX's ROE is -1.44%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BJDX is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check CSII's competition here
BJDX vs INMD Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, INMD has a market cap of 812.4M. Regarding current trading prices, BJDX is priced at $4.65, while INMD trades at $13.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas INMD's P/E ratio is 9.90. In terms of profitability, BJDX's ROE is -1.44%, compared to INMD's ROE of +0.13%. Regarding short-term risk, BJDX is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check INMD's competition here
BJDX vs CRY Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, BJDX is priced at $4.65, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas CRY's P/E ratio is 425.71. In terms of profitability, BJDX's ROE is -1.44%, compared to CRY's ROE of +0.03%. Regarding short-term risk, BJDX is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check CRY's competition here
BJDX vs SIBN Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, SIBN has a market cap of 674.6M. Regarding current trading prices, BJDX is priced at $4.65, while SIBN trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas SIBN's P/E ratio is -39.00. In terms of profitability, BJDX's ROE is -1.44%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, BJDX is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check SIBN's competition here
BJDX vs SSII Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, SSII has a market cap of 658.4M. Regarding current trading prices, BJDX is priced at $4.65, while SSII trades at $3.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas SSII's P/E ratio is -65.80. In terms of profitability, BJDX's ROE is -1.44%, compared to SSII's ROE of -0.23%. Regarding short-term risk, BJDX is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check SSII's competition here
BJDX vs CBLL Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, CBLL has a market cap of 655.6M. Regarding current trading prices, BJDX is priced at $4.65, while CBLL trades at $17.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas CBLL's P/E ratio is -10.67. In terms of profitability, BJDX's ROE is -1.44%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, BJDX is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check CBLL's competition here
BJDX vs SRDX Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BJDX is priced at $4.65, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BJDX's ROE is -1.44%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, BJDX is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check SRDX's competition here
BJDX vs TCMD Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, TCMD has a market cap of 582.6M. Regarding current trading prices, BJDX is priced at $4.65, while TCMD trades at $25.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas TCMD's P/E ratio is 29.69. In terms of profitability, BJDX's ROE is -1.44%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, BJDX is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check TCMD's competition here
BJDX vs APEN Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BJDX is priced at $4.65, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas APEN's P/E ratio is -9.43. In terms of profitability, BJDX's ROE is -1.44%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BJDX is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check APEN's competition here
BJDX vs BVS Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, BVS has a market cap of 578.6M. Regarding current trading prices, BJDX is priced at $4.65, while BVS trades at $8.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas BVS's P/E ratio is 20.83. In terms of profitability, BJDX's ROE is -1.44%, compared to BVS's ROE of +0.16%. Regarding short-term risk, BJDX is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check BVS's competition here
BJDX vs BWAY Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, BWAY has a market cap of 565.2M. Regarding current trading prices, BJDX is priced at $4.65, while BWAY trades at $14.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas BWAY's P/E ratio is 68.62. In terms of profitability, BJDX's ROE is -1.44%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, BJDX is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check BWAY's competition here
BJDX vs ZIMV Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BJDX is priced at $4.65, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BJDX's ROE is -1.44%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, BJDX is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check ZIMV's competition here
BJDX vs NPCE Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, NPCE has a market cap of 516.9M. Regarding current trading prices, BJDX is priced at $4.65, while NPCE trades at $15.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas NPCE's P/E ratio is -23.32. In terms of profitability, BJDX's ROE is -1.44%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, BJDX is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check NPCE's competition here
BJDX vs CERS Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, CERS has a market cap of 514.9M. Regarding current trading prices, BJDX is priced at $4.65, while CERS trades at $2.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas CERS's P/E ratio is -51.40. In terms of profitability, BJDX's ROE is -1.44%, compared to CERS's ROE of -0.15%. Regarding short-term risk, BJDX is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check CERS's competition here
BJDX vs CTKB Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, CTKB has a market cap of 514M. Regarding current trading prices, BJDX is priced at $4.65, while CTKB trades at $3.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas CTKB's P/E ratio is -6.86. In terms of profitability, BJDX's ROE is -1.44%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, BJDX is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check CTKB's competition here
BJDX vs CLPT Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, CLPT has a market cap of 504.1M. Regarding current trading prices, BJDX is priced at $4.65, while CLPT trades at $17.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas CLPT's P/E ratio is -16.81. In terms of profitability, BJDX's ROE is -1.44%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, BJDX is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check CLPT's competition here
BJDX vs KIDS Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, KIDS has a market cap of 466.7M. Regarding current trading prices, BJDX is priced at $4.65, while KIDS trades at $18.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas KIDS's P/E ratio is -10.82. In terms of profitability, BJDX's ROE is -1.44%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, BJDX is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check KIDS's competition here
BJDX vs VREX Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, VREX has a market cap of 429.4M. Regarding current trading prices, BJDX is priced at $4.65, while VREX trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas VREX's P/E ratio is -5.10. In terms of profitability, BJDX's ROE is -1.44%, compared to VREX's ROE of -0.18%. Regarding short-term risk, BJDX is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check VREX's competition here
BJDX vs PACB Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, PACB has a market cap of 416.2M. Regarding current trading prices, BJDX is priced at $4.65, while PACB trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas PACB's P/E ratio is -3.27. In terms of profitability, BJDX's ROE is -1.44%, compared to PACB's ROE of -4.88%. Regarding short-term risk, BJDX is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check PACB's competition here
BJDX vs DCTH Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, DCTH has a market cap of 411.8M. Regarding current trading prices, BJDX is priced at $4.65, while DCTH trades at $11.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas DCTH's P/E ratio is 1193.00. In terms of profitability, BJDX's ROE is -1.44%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, BJDX is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check DCTH's competition here
BJDX vs VMD Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, VMD has a market cap of 403.7M. Regarding current trading prices, BJDX is priced at $4.65, while VMD trades at $10.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas VMD's P/E ratio is 28.46. In terms of profitability, BJDX's ROE is -1.44%, compared to VMD's ROE of +0.11%. Regarding short-term risk, BJDX is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check VMD's competition here
BJDX vs OFIX Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, OFIX has a market cap of 373.1M. Regarding current trading prices, BJDX is priced at $4.65, while OFIX trades at $9.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas OFIX's P/E ratio is -6.15. In terms of profitability, BJDX's ROE is -1.44%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, BJDX is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check OFIX's competition here
BJDX vs AVR Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, AVR has a market cap of 349.5M. Regarding current trading prices, BJDX is priced at $4.65, while AVR trades at $9.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas AVR's P/E ratio is -4.28. In terms of profitability, BJDX's ROE is -1.44%, compared to AVR's ROE of -1.24%. Regarding short-term risk, BJDX is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check AVR's competition here
BJDX vs MASS Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, MASS has a market cap of 324.4M. Regarding current trading prices, BJDX is priced at $4.65, while MASS trades at $8.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas MASS's P/E ratio is -8.85. In terms of profitability, BJDX's ROE is -1.44%, compared to MASS's ROE of -0.26%. Regarding short-term risk, BJDX is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check MASS's competition here
BJDX vs LAB Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, LAB has a market cap of 316.2M. Regarding current trading prices, BJDX is priced at $4.65, while LAB trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas LAB's P/E ratio is -6.23. In terms of profitability, BJDX's ROE is -1.44%, compared to LAB's ROE of -0.21%. Regarding short-term risk, BJDX is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check LAB's competition here
BJDX vs SMLR Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BJDX is priced at $4.65, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BJDX's ROE is -1.44%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, BJDX is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check SMLR's competition here
BJDX vs ELMD Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, ELMD has a market cap of 310.2M. Regarding current trading prices, BJDX is priced at $4.65, while ELMD trades at $37.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas ELMD's P/E ratio is 32.02. In terms of profitability, BJDX's ROE is -1.44%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, BJDX is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check ELMD's competition here
BJDX vs PMI Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, PMI has a market cap of 295.9M. Regarding current trading prices, BJDX is priced at $4.65, while PMI trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas PMI's P/E ratio is -0.25. In terms of profitability, BJDX's ROE is -1.44%, compared to PMI's ROE of +4.99%. Regarding short-term risk, BJDX is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check PMI's competition here
BJDX vs SENS Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, SENS has a market cap of 279.6M. Regarding current trading prices, BJDX is priced at $4.65, while SENS trades at $6.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas SENS's P/E ratio is -3.40. In terms of profitability, BJDX's ROE is -1.44%, compared to SENS's ROE of -1.30%. Regarding short-term risk, BJDX is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check SENS's competition here
BJDX vs SGHT Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, SGHT has a market cap of 272.6M. Regarding current trading prices, BJDX is priced at $4.65, while SGHT trades at $4.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas SGHT's P/E ratio is -7.16. In terms of profitability, BJDX's ROE is -1.44%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, BJDX is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check SGHT's competition here
BJDX vs TMCI Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, TMCI has a market cap of 260.1M. Regarding current trading prices, BJDX is priced at $4.65, while TMCI trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas TMCI's P/E ratio is -4.18. In terms of profitability, BJDX's ROE is -1.44%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, BJDX is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check TMCI's competition here
BJDX vs MGRM Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BJDX is priced at $4.65, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas MGRM's P/E ratio is -11.11. In terms of profitability, BJDX's ROE is -1.44%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, BJDX is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check MGRM's competition here
BJDX vs CATX Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, CATX has a market cap of 229.8M. Regarding current trading prices, BJDX is priced at $4.65, while CATX trades at $2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas CATX's P/E ratio is -2.11. In terms of profitability, BJDX's ROE is -1.44%, compared to CATX's ROE of -0.42%. Regarding short-term risk, BJDX is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check CATX's competition here
BJDX vs NVRO Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BJDX is priced at $4.65, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BJDX's ROE is -1.44%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BJDX is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check NVRO's competition here
BJDX vs EYES Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, BJDX is priced at $4.65, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas EYES's P/E ratio is N/A. In terms of profitability, BJDX's ROE is -1.44%, compared to EYES's ROE of -2.64%. Regarding short-term risk, BJDX is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check EYES's competition here
BJDX vs PROF Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, PROF has a market cap of 198.8M. Regarding current trading prices, BJDX is priced at $4.65, while PROF trades at $6.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas PROF's P/E ratio is -5.30. In terms of profitability, BJDX's ROE is -1.44%, compared to PROF's ROE of -0.71%. Regarding short-term risk, BJDX is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check PROF's competition here
BJDX vs BSGM Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BJDX is priced at $4.65, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BJDX's ROE is -1.44%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, BJDX is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check BSGM's competition here
BJDX vs RXST Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, RXST has a market cap of 190M. Regarding current trading prices, BJDX is priced at $4.65, while RXST trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas RXST's P/E ratio is -4.06. In terms of profitability, BJDX's ROE is -1.44%, compared to RXST's ROE of -0.17%. Regarding short-term risk, BJDX is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check RXST's competition here
BJDX vs ANIK Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, ANIK has a market cap of 189.3M. Regarding current trading prices, BJDX is priced at $4.65, while ANIK trades at $14.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas ANIK's P/E ratio is -18.01. In terms of profitability, BJDX's ROE is -1.44%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, BJDX is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check ANIK's competition here
BJDX vs FOCL Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, FOCL has a market cap of 183.7M. Regarding current trading prices, BJDX is priced at $4.65, while FOCL trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas FOCL's P/E ratio is -5.98. In terms of profitability, BJDX's ROE is -1.44%, compared to FOCL's ROE of -1.37%. Regarding short-term risk, BJDX is more volatile compared to FOCL. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check FOCL's competition here
BJDX vs MDGS Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BJDX is priced at $4.65, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BJDX's ROE is -1.44%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BJDX is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check MDGS's competition here
BJDX vs EDAP Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, BJDX is priced at $4.65, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas EDAP's P/E ratio is -5.80. In terms of profitability, BJDX's ROE is -1.44%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, BJDX is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check EDAP's competition here
BJDX vs APYX Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, APYX has a market cap of 176.3M. Regarding current trading prices, BJDX is priced at $4.65, while APYX trades at $4.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas APYX's P/E ratio is -19.14. In terms of profitability, BJDX's ROE is -1.44%, compared to APYX's ROE of -0.91%. Regarding short-term risk, BJDX is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check APYX's competition here
BJDX vs INGN Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, INGN has a market cap of 172.5M. Regarding current trading prices, BJDX is priced at $4.65, while INGN trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas INGN's P/E ratio is -7.00. In terms of profitability, BJDX's ROE is -1.44%, compared to INGN's ROE of -0.13%. Regarding short-term risk, BJDX is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check INGN's competition here
BJDX vs QIPT Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BJDX is priced at $4.65, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BJDX's ROE is -1.44%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, BJDX is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check QIPT's competition here
BJDX vs TLSI Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, TLSI has a market cap of 147.5M. Regarding current trading prices, BJDX is priced at $4.65, while TLSI trades at $3.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas TLSI's P/E ratio is -2.74. In terms of profitability, BJDX's ROE is -1.44%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, BJDX is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check TLSI's competition here
BJDX vs QTRX Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, QTRX has a market cap of 135.7M. Regarding current trading prices, BJDX is priced at $4.65, while QTRX trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas QTRX's P/E ratio is -1.23. In terms of profitability, BJDX's ROE is -1.44%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, BJDX is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for BJDX.Check QTRX's competition here
BJDX vs CVRX Comparison June 2026
BJDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BJDX stands at 2.1M. In comparison, CVRX has a market cap of 128.2M. Regarding current trading prices, BJDX is priced at $4.65, while CVRX trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BJDX currently has a P/E ratio of -1.21, whereas CVRX's P/E ratio is -2.40. In terms of profitability, BJDX's ROE is -1.44%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, BJDX is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for BJDX.Check CVRX's competition here